Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corticotropin - Mallinckrodt

Next Previous
X
Search
Drug Profile

Corticotropin - Mallinckrodt

Alternative Names: ACTH gel; Acthar; Acthar Gel therapy; Adrenocorticotropin gel - Mallinckrodt; H.P. Acthar Gel; Repository corticotropin injection - Mallinckrodt; SelfJect™

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aventis Pharmaceuticals
  • Developer Mallinckrodt plc
  • Class Anterior pituitary hormones; Anti-inflammatories; Antiepileptic drugs; Antirheumatics; Corticosteroids; Eye disorder therapies; Hypothalamic hormones; Urologics
  • Mechanism of Action Corticotropin receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Infantile spasms
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Infantile spasms; Juvenile rheumatoid arthritis; Membranous glomerulonephritis; Multiple sclerosis; Nephrotic syndrome; Ocular inflammation; Polymyositis; Psoriatic arthritis; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus
  • Phase II Amyotrophic lateral sclerosis; Scleritis
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 06 Aug 2024 Mallinckrodt launches Corticotropin injector (SelfJect™) in Inflammatory disorders and Autoimmune disorders in USA
  • 09 May 2024 Mallinckrodt expects to launch Corticotropin injector (SelfJect) in the USA in the third quarter of 2024
  • 29 Feb 2024 The US FDA approves sNDA application for Corticotropin injector (SelfJect™) in Inflammatory disorders and Autoimmune disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top